Cargando…
Arginine methylation: the promise of a ‘silver bullet’ for brain tumours?
Despite intense research efforts, our pharmaceutical repertoire against high-grade brain tumours has not been able to increase patient survival for a decade and life expectancy remains at less than 16 months after diagnosis, on average. Inhibitors of protein arginine methyltransferases (PRMTs) have...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107164/ https://www.ncbi.nlm.nih.gov/pubmed/33404912 http://dx.doi.org/10.1007/s00726-020-02937-x |